Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

GAY LYNNE GOSS

NPI
1235344268
CMS profile
10967627
Location
SAN FRANCISCO, CA

General Payments · PY2022–2023

$10,399.77

  • Reported across 17 records
  • CMS publication 2026-01-23

Latest program year · PY2023

$10,326.70

16 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2023 · sorted by reported total

By paying entity

PY2023 · sorted by reported total

Paying entityAmountRecords
Astellas Pharma US Inc $10,169.46 14
Sumitomo Pharma America, Inc. $92.33 1
ABBVIE INC. $64.91 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $73.07 1
PY2023 $10,326.70 16

Payment records · PY2023 (16)

Sorted by paying entity, then date · as published by CMS

Program year 2023 2022 Record-level detail is published for PY2023; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $64.91 10/30/2023 Food and Beverage Undisputed 01/23/2026 1005358347 CMS
Astellas Pharma US Inc $143.58 01/24/2023 Food and Beverage Undisputed 01/23/2026 1033880403 CMS
Astellas Pharma US Inc $111.11 01/24/2023 Travel and Lodging Undisputed 01/23/2026 1033883361 CMS
Astellas Pharma US Inc $237.81 01/24/2023 Travel and Lodging Undisputed 01/23/2026 1033883367 CMS
Astellas Pharma US Inc $224.00 01/24/2023 Travel and Lodging Undisputed 01/23/2026 1033883381 CMS
Astellas Pharma US Inc $311.38 01/25/2023 Food and Beverage Undisputed 01/23/2026 1033883851 CMS
Astellas Pharma US Inc $3,486.00 01/25/2023 Consulting Fee Undisputed 01/23/2026 1033883871 CMS
Astellas Pharma US Inc $220.16 01/25/2023 Travel and Lodging Undisputed 01/23/2026 1033886047 CMS
Astellas Pharma US Inc $2,870.00 06/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1034130639 CMS
Astellas Pharma US Inc $159.82 06/01/2023 Travel and Lodging Undisputed 01/23/2026 1034131215 CMS
Astellas Pharma US Inc $115.01 08/31/2023 Food and Beverage Undisputed 01/23/2026 1034467995 CMS
Astellas Pharma US Inc $208.95 08/31/2023 Travel and Lodging Undisputed 01/23/2026 1034468459 CMS
Astellas Pharma US Inc $1,720.00 08/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1034468465 CMS
Astellas Pharma US Inc $236.64 08/31/2023 Travel and Lodging Undisputed 01/23/2026 1034468471 CMS
Astellas Pharma US Inc $125.00 10/30/2023 Food and Beverage Undisputed 01/23/2026 1034626419 CMS
Sumitomo Pharma America, Inc. $92.33 10/31/2023 Food and Beverage Undisputed 01/23/2026 1031138809 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2022, 2023
Source files
Dataset page · Bulk file · PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.